Is Celldex Therapeutics (CLDX) Stock the Next Clovis Oncology (CLVS)?

- February 25, 2017

A BNL Member emailed our biotech specialist Liam Hunter a question about diversification and CLDX stock:

“Liam, I am new to investing with about $20,000 to start. I plan to add $6,000/year over the next 10 years which exceeds Brian’s “Retire A Millionaire” plan. I bought two stocks, one is Celldex Therapeutics, Inc (NASDAQ:CLDX). I know it is a high risk stock, but I also think it could go a lot higher. Would you own CLDX and do you think Glembatumab is a real drug?”

Liam’s take on CLDX stock

A picture is worth a 1000 words, and the following pretty much illustrates the entire story with Celldex Therapeutics, Inc (NASDAQ:CLDX) over the last few years.

Strong data with Glembatumab vedotin (CDX-011) allowed CLDX stock to rise from $2 to nearly $40 in just two years. Then, realization set in that Celldex needed a lot more data on Glembatumab vedotin to take it to market, and the attention turned to the company’s most mature candidate, Rintega.

Rintega ended up failing its Phase 3 trial in treating glioblastoma multiforme, brain cancer, patients. That, coupled with the stoppage of other trials forced CLDX stock owners to step back and consider that maybe they rushed into thinking that Celldex was the next Celgene.

The rest is history, with CLDX stock giving back all of its gains and essentially no hope or promise baked into Celldex valuation that Glembatumab vedotin will be a success.

With that said, if Glembatumab vedotin were to be successful in its Phase 2 trial, a trial that is large enough to support an FDA approval, then CLDX stock would end up following the pattern of one Clovis Oncology (NASDAQ:CLVS).

As seen, CLVS stock surged in 2013 behind data. It then fell in late 2015 because of data, and has since bounced nearly 400% off its lows thanks to data. Sarepta Therapeutics (NASDAQ:SRPT) is another like CLVS stock.

In April to July 2016 sentiment was lowest with no hope for CLVS stock owners. That’s where CLDX stock owners find themselves today. Can it be turned around? Does Celldex Therapeutics and Glembatumab vedotin have a realistic chance to right the wrong? To answer this very specific BNL Member question, BNL Members can continue to read.

As always, my analysis and opinions are for BNL Members only.

Biotech Hunter: CLDX stock

The rest of this content is exclusive to BNL Members only. (Unlock All Content & Much More)
  • Access all research reports, unlock hidden content, & follow stock coverage on more than 60 companies,
  • Know what stocks are being bought, sold, and held in the market beating BNL Portfolio, David's Dividend Portfolio, and Eddy's Options.
  • Get email notifications and mobile alerts the minute a trade is made. 
  • Join the fastest growing community of investors in the market, and engage with 100s of BNL Members in our Members Only section.

Learn More about BNL Membership and its no risk, no contract, guaranteed results policy!

Get our All Access Package for $85/month!

This entry was posted in Biotech Hunter, Healthcare & Biotech, Members Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

One Trackback

  1. […] couple weeks ago I published a post explaining why Celldex Therapeutics Inc (NASDAQ:CLDX) could become the next Clovis Oncology. I used the […]

Post a Comment

You must be logged in to post a comment.







Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.


Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!